Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
Marit J. van Gils, A. H. Ayesha Lavell, Karlijn van der Straten, et al.
PLoS Medicine (2022) Vol. 19, Iss. 5, pp. e1003991-e1003991
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

T Cell Responses to SARS-CoV-2
Alessandro Sette, John Sidney, Shane Crotty
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 343-373
Closed Access | Times Cited: 114
Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron
Karlijn van der Straten, Denise Guerra, Marit J. van Gils, et al.
Immunity (2022) Vol. 55, Iss. 9, pp. 1725-1731.e4
Open Access | Times Cited: 85
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1760-1774
Open Access | Times Cited: 80
ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Magnus A. G. Hoffmann, Zhi Yang, Kathryn E. Huey‐Tubman, et al.
Cell (2023) Vol. 186, Iss. 11, pp. 2380-2391.e9
Open Access | Times Cited: 42
Mapping the antigenic diversification of SARS-CoV-2
Karlijn van der Straten, Denise Guerra, Marit J. van Gils, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 56
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
Wenjuan Du, Daniel L. Hurdiss, Dubravka Drabek, et al.
Science Immunology (2022) Vol. 7, Iss. 73
Open Access | Times Cited: 51
Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study
Marta Selma‐Royo, Christine Bäuerl, Desirée Mena‐Tudela, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 47
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1822-1849
Open Access | Times Cited: 44
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Rontgene Solante, Carlos Álvarez, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 1-16
Open Access | Times Cited: 41
Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development
Md. Aminul Islam, Shatila Shahi, Abdullah Al Marzan, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 21
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Georg M. N. Behrens, Joana Barros‐Martins, Anne Cossmann, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
Julien Favresse, Constant Gillot, Jean‐Louis Bayart, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 34
Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals
Stijn P. Andeweg, Harry Vennema, Irene Veldhuijzen, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 684
Open Access | Times Cited: 33
Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines
Astrid Korning Hvidt, Eva Anna Marianne Baerends, Ole S. Søgaard, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 28
Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study
Aric A. Prather, Ethan G. Dutcher, James E. Robinson, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 19
Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Jeffrey P. Townsend, Hayley B. Hassler, Alex Dornburg
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Open Access | Times Cited: 18
Post-vaccination T cell immunity to omicron
Henning Jacobsen, Viviana Cobos Jiménez, Ioannis Sitaras, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies
Anna L. Beukenhorst, Clarissa M. Koch, Christoforos Hadjichrysanthou, et al.
European Journal of Epidemiology (2023) Vol. 38, Iss. 3, pp. 237-242
Open Access | Times Cited: 12
Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
Laura Radić, Kwinten Sliepen, Victor Yin, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106540-106540
Open Access | Times Cited: 12
Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity
Leanne P. M. van Leeuwen, Marloes Grobben, Corine H. GeurtsvanKessel, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1104-1117
Open Access | Times Cited: 12
Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
Billy J. Gardner, A. Marm Kilpatrick
Viruses (2024) Vol. 16, Iss. 3, pp. 479-479
Open Access | Times Cited: 4
COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
Dorota Zarębska‐Michaluk, Chenlin Hu, Michał Brzdęk, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1223-1223
Open Access | Times Cited: 20
Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital
Vidya Arankalle, A. G. Kulkarni, Ruta Kulkarni, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern
Louisa Ruhl, Jenny F. Kühne, Kerstin Beushausen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents
Naomi S. Coombes, Kevin R. Bewley, Yann Le Duff, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 633-633
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top